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In leukopenic mice with severe systemic candidiasis, single-dose treatment (5 mg of amphotericin B [AMB]/
kg of body weight) with long-circulating polyethylene glycol-coated AMB liposomes (PEG-AMB-LIP) resulted
in zero mortality and a significant reduction in the number of viable Candida albicans in the kidney, whereas
70% mortality was seen in mice treated with five daily doses of AmBisome (5 mg of AMB/kg z day). When the
first of five daily doses of AmBisome was combined with a single low dose of Fungizone (0.1 mg of AMB/kg),
the efficacy was equal to that of PEG-AMB-LIP.
Fungizone (amphotericin B [AMB] deoxycholate) remains
the therapy of choice for most invasive fungal infections, but
the use of this drug is significantly limited by its toxic side ef-
fects. Lipid formulations of AMB have been developed by the
pharmaceutical industry, with the primary aim of a reduction
of AMB’s toxicity. Strikingly, it is not well recognized that the
reduction of AMB’s toxicity following lipid formulation seems
to be associated with a substantial reduction of the drug’s
direct antifungal activity. It has been previously reported that
the in vitro activity of AmBisome during short-term exposure
of Candida albicans was significantly less than that of Fungi-
zone (4, 5, 7). Furthermore, various in vivo studies have clearly
demonstrated that high dosages of AMB-lipid formulations
are often needed for a treatment to be effective (3, 5, 7). Re-
cently, we were able to show that it is now possible, by using a
lipid formulation, to substantially reduce the toxicity of AMB
without reducing its direct antifungal activity (7). A new type of
liposomal AMB in which AMB is complexed to a hydrophilic
phospholipid derivative of polyethylene glycol (PEG-AMB-
LIP) was prepared in our laboratory. The PEG-AMB-LIP for-
mulation shows three characteristics that are expected to be
important for improved antifungal efficacy (6, 7): low toxicity,
high direct antifungal activity, and prolonged circulation time
of intact liposomes in blood. Prolonged blood residence of
intact liposomes may be important for increased accumulation
of liposomal AMB at sites of fungal infection outside the
mononuclear phagocyte system, such as the kidney and lung (1,
2).
In a previous study with our model of severe invasive C. al-
bicans infection, it was shown that treatment with a single dose
of PEG-AMB-LIP (5 mg of AMB/kg of body weight) resulted
in decreasing numbers of viable C. albicans in the kidney within
a short period of time after inoculation with this organism.
This effect could not be achieved with AmBisome at the same
dosage; however, a much higher dosage of AmBisome (29 mg
of AMB/kg) was as effective as PEG-AMB-LIP. In the present
study, the significance of the high direct antifungal activity of
PEG-AMB-LIP for the treatment of acute severe systemic
candidiasis is further explored. The effect of early or delayed
treatment with a single dose of PEG-AMB-LIP was compared
with that of single- or multidose treatment with AmBisome.
Furthermore, the potential benefit of adding a single low dose
of Fungizone to the first dose of AmBisome was investigated.
Sabouraud dextrose agar was from Unipath Ltd. (Basing-
stoke, England). AMB and Fungizone were kindly provided by
Bristol Myers-Squibb (Woerden, The Netherlands). AmBisome
was from NeXstar Pharmaceuticals, Inc. (San Dimas, Calif.).
Hydrogenated soybean phosphatidylcholine (HSPC) and a
polyethylene glycol 1900 derivative of distearoylphosphatidyl-
ethanolamine (PEG-DSPE) were obtained from Avanti Polar
Lipids, Inc. (Alabaster, Ala.). Dimethyl sulfoxide was from
Janssen Chimica (Tilburg, The Netherlands). Cyclophospha-
mide and cholesterol (Chol) were from Sigma (St. Louis,
Mo.). Chloroform and methanol were from Merck (Darm-
stadt, Germany). C. albicans ATCC 44858 was used (5).
Specific-pathogen-free 12- to 20-week-old female BALB/c
mice were obtained from Iffa Credo (L’Arbresle, France).
PEG-DSPE–HSPC–Chol–AMB in a molar ratio of 0.21:
1.79:1:0.32 (PEG-AMB-LIP) and placebo liposomes (devoid
of AMB) were prepared as described previously (6, 7). Am-
Bisome, consisting of HSPC-Chol-distearoylphosphatidylglyc-
erol-AMB in a molar ratio of 2:1:0.8:0.4, was provided as a
lyophilized preparation. The powder was reconstituted accord-
ing to the manufacturer’s instructions.
Leukopenic mice were infected with C. albicans as previous-
ly described (7). The treatment regimens studied were as fol-
lows: (i) single-dose PEG-AMB-LIP, (ii) single- or multidose
AmBisome, (iii) multidose AmBisome combined with a single
dose of Fungizone, and (iv) single-dose Fungizone.
(i) Single-dose PEG-AMB-LIP. PEG-AMB-LIP was admin-
istered intravenously (i.v.) as a single dose of the maximum tol-
erated dosage of 5 mg of AMB/kg (7). Treatment was started
at either 6, 16, or 20 h after C. albicans inoculation.
(ii) Single- or multidose AmBisome. AmBisome was admin-
istered i.v. either as a single dose of 5 mg of AMB/kg or daily
at 5 mg of AMB/kg z day for three or five consecutive days.
Treatment was started at either 6, 16, or 20 h after C. albicans
inoculation.
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(iii) Multidose AmBisome combined with a single dose of
Fungizone. The first of five daily doses of AmBisome (5 mg of
AMB/kg z day) was administered at 20 h after inoculation with
C. albicans and combined with a single i.v. dose of the maxi-
mum tolerated dosage (0.1 mg of AMB/kg) of Fungizone (5).
The two agents were administered separately, with the first
dose of AmBisome being given directly after Fungizone.
(iv) Single-dose Fungizone. Fungizone, at 0.1 mg of AMB/
kg, was administered i.v. 20 h after C. albicans inoculation.
The efficacy of treatment was assessed as previously de-
scribed (7). In the present study, only the numbers of viable
C. albicans in the kidneys were determined, since it was pre-
viously shown (5, 7) that in this animal model the kidney is the
most severely infected organ. Differences in C. albicans CFU
between the various treatment groups were analyzed by the
Mann-Whitney test.
By increasing the delay of the start of treatment, the efficacy
of treatment in relation to the severity of infection could be
investigated. This was reflected in increasing numbers (P #
0.01) of viable C. albicans in the kidneys at the start of treat-
ment (Table 1). The effect of early or delayed treatment with
a single dose of PEG-AMB-LIP versus single- or multidose
AmBisome treatment is presented in Table 1. When Am-
Bisome treatment was started 6 h after C. albicans inoculation,
five daily doses (5 mg/kg z day) were needed to significantly
reduce the number of viable C. albicans at 7 days after inocu-
lation compared to the number at the start of treatment. The
rate of response to this therapy was, thus, relatively low.
In this model of acute severe systemic candidiasis, in which
untreated animals start to die 24 h after C. albicans inocula-
tion, the efficacy of a 5-day AmBisome treatment regimen after
a delay in the start of treatment was questioned. When treat-
ment was delayed until 16 h after inoculation, 10% of the
animals died after five daily doses of AmBisome. The further
delay in treatment to 20 h after inoculation resulted in an
increase in mortality to 70%. In sharp contrast, a single dose of
PEG-AMB-LIP administered at 20 h after inoculation still
resulted in zero mortality and a significant reduction in the
number of viable C. albicans in the kidney. The present study
shows that the high efficacy observed for PEG-AMB-LIP at a
single-dose administration could not be matched by a multi-
dose regimen of AmBisome, although the latter results in pro-
longed blood residence. Probably the high direct antifungal
activity of AMB is of major importance in the successful treat-
ment of severely infected animals with PEG-AMB-LIP: treat-
ment with PEG-AMB-LIP resulted in a rapid response in terms
of decreasing numbers of viable C. albicans in the kidney, whereas
AmBisome treatment did not.
Apparently, AMB in PEG-AMB-LIP is readily available for
immediate antifungal activity. To gain more insight into the
mechanism by which PEG-AMB-LIP exerts its rapid antifun-
gal effect, factors important for the specific transfer of AMB
from PEG-AMB-LIP to fungal cells are presently under inves-
tigation. The possibility of a slight release of AMB from PEG-
AMB-LIP in the blood after i.v. administration cannot be ex-
TABLE 1. Effect of early or delayed treatment with a single dose of PEG-AMB-LIP versus single- or multidose
AmBisome on survival of leukopenic micea and growth of C. albicans in the kidney
Time of start of treatment
(h postinoculation) Treatment
b Daily dose
(mg/kg)
No. of
doses
Log10 CFU/kidney in surviving mice on dayc:
0 3 7
6 None 3.20 6 0.16
Placebo 5.94 6 0.11 (50) 6.86 6 0.07 (30)
PEG-AMB-LIP 5 1 1.04 6 0.39d (100 1.16 6 0.70d (100)
AmBisome 5 1 3.28 6 0.20 (100) 3.47 6 0.41 (100)
AmBisome 5 3 3.08 6 0.26 (100) 3.46 6 0.57 (100)
AmBisome 5 5 2.90 6 0.44 (100) 2.63 6 0.46d (100)
16 None 4.01 6 0.22
PEG-AMB-LIP 5 1 2.29 6 0.42d (100) 1.35 6 0.51d,e (100)
AmBisome 5 5 4.79 6 0.40 (90) 3.43 6 0.38 (90)
20 None 4.34 6 0.19
PEG-AMB-LIP 5 1 2.88 6 0.38d (100) 2.31 6 0.19d,e (100)
AmBisome 5 5 5.39 6 0.45 (60) 4.57 6 1.11 (30)
a Leukopenic mice were inoculated i.v. at time zero with 3 3 104 CFU of C. albicans; untreated mice died between 24 h and 8 days after C. albicans inoculation.
b PEG-AMB-LIP, AmBisome, and the placebo were administered i.v.
c The effect of treatment was determined at day 3 (n 5 10) as well as day 7 (n 5 10) after inoculation. Each value represents the geometric mean 6 the standard
deviation. The numbers in parentheses indicate the percentages of surviving mice. Values at day 0 are log10 CFU/kidney at the start of treatment.
d P # 0.002 compared with the number of CFU at the start of treatment.
e P # 0.002 compared with the number of CFU at day 3 after inoculation.
TABLE 2. Effect of multidose AmBisome treatment with
or without a single dose of Fungizone on survival
of leukopenic micea and growth of
C. albicans in the kidney
Treatmentb Daily dose(mg/kg)
No. of
doses
Log10 CFU/kidney in surviving
mice on day c:
3 7
AmBisome 5 5 5.39 6 0.45 (60) 4.57 6 1.11 (30)
Fungizone 1
AmBisome
0.1 1 5 1 1 5 3.00 6 0.17d (100) 2.06 6 0.31d,e (100)
Fungizone 0.1 1 5.67 6 0.12 (40) 6.38 6 0.41 (40)
a Leukopenic mice were inoculated i.v. at time zero with 3 3 104 CFU of
C. albicans; untreated mice died between 24 h and 8 days after C. albicans
inoculation.
b AmBisome and Fungizone were administered i.v. at 20 h after C. albicans
inoculations. In the combination treatment, both agents were administered sep-
arately, with the first dose of AmBisome being given directly after Fungizone.
c The effect of treatment was determined at day 3 (n 5 10) as well as day 7 (n 5
10) after inoculation. The log10 CFU/kidney at the start of treatment (day 0) was
4.34 6 0.19. Each value represents the geometric mean 6 the standard deviation.
The numbers in parentheses indicate the percentages of surviving mice (see also
the legend to Table 1).
d P # 0.002 compared with the number of CFU at the start of treatment.
e P # 0.002 compared with the number of CFU at day 3 after inoculation.
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cluded, although it has been previously shown that during
circulation AMB is tightly associated with the liposomes in
PEG-AMB-LIP (6).
The second part of the study involved investigating whether
a lack of direct availability of AMB in AmBisome might be
responsible for the low efficacy of that drug in severely infected
mice. At 20 h after C. albicans inoculation, the first of five daily
doses of AmBisome was combined with a single low dose of
Fungizone (0.1 mg of AMB/kg) (Table 2). Strikingly, the effi-
cacy of this combined treatment was equal to that of PEG-
AMB-LIP (Tables 1 and 2). After receiving a single low dose
of Fungizone alone, the animals died (Table 2). The observa-
tion that in severe invasive fungal infection the efficacy of
treatment with AmBisome can be greatly improved by addition
of a single low dose of Fungizone in the early phase of treat-
ment may be of great clinical significance.
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